Therapeutic effect of TCM directional perfusion therapy on pleural thickening and adhesion formation in tuberculous pleurisy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024943

Enrollment

Unknown

Registered

2019-08-04

Start date

2019-08-02

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculous pleurisy

Interventions

control group:Chinese medicine perfusion therapy

Placebo group:Permeabilization therapy

treatment group:Chinese medicine directed permeabilization treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnosis of tuberculous pleurisy in Chinese and Western medicine. (2) Combined with pleural thickening or adhesions.

Exclusion criteria

Exclusion criteria: (1) Unconsciousness and bedridden patients; (2) Allergic patients with electrodes; (3) Can not complete a course of treatment (7 days) to treat patients; (4) Critically ill, requiring mechanical ventilation; (5) Severe heart and brain dysfunction; (6) Liver and kidney dysfunction; (7) Hematopoietic dysfunction; (8) History of mental illness; (9) Pregnancy and lactation Women; (10) Used glucocorticoids within 1 month; (11) Participated in other clinical trials in the past 1 month.

Design outcomes

Primary

Measure	Time frame
Pleural thickness;	—

Countries

China

Contacts

Public ContactJie Li

Jiangxi Provincial Chest Hospital

lijie_3608@126.com+86 15270831364

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026